Prediction of glycaemic control in young children and adolescents with type 1 diabetes mellitus using mixed-effects logistic regression modelling by Esdonk, M.J. van et al.
RESEARCH ARTICLE
Prediction of glycaemic control in young
children and adolescents with type 1 diabetes
mellitus using mixed-effects logistic
regression modelling
Michiel Joost van Esdonk1¤*, Bonnie Tai2, Andrew Cotterill3, Bruce Charles1,
Stefanie Hennig1
1 School of Pharmacy, Pharmacy Australia Centre of Excellence (PACE), The University of Queensland,
Woolloongabba, Queensland, Australia, 2 Pharmacy Department, The Prince Charles Hospital, Chermside,
Queensland, Australia, 3 Lady Cilento Children’s Hospital, South Brisbane and Queensland Paediatric
Endocrinology, Woolloongabba, Queensland, Australia
¤ Current address: Division of Pharmacology, Cluster Systems Pharmacology, Leiden Academic Centre for
Drug Research, Leiden University, Leiden, The Netherlands
* m.j.van.esdonk@lacdr.leidenuniv.nl
Abstract
Objectives
Glycaemic control in children and adolescents with type 1 diabetes mellitus can be challeng-
ing, complex and influenced by many factors. This study aimed to identify patient character-
istics that were predictive of satisfactory glycaemic control in the paediatric population using
a logistic regression mixed-effects (population) modelling approach.
Methods
The data were obtained from 288 patients aged between 1 and 22 years old recorded retro-
spectively over 3 years (1852 HbA1c observations). HbA1c status was categorised as ‘satis-
factory’ or ‘unsatisfactory’ glycaemic control, using an a priori cut-off value of HbA1c 9%
(75 mmol/mol), as used routinely by the hospital’s endocrine paediatricians. Patients’ char-
acteristics were tested as covariates in the model as potential predictors of glycaemic
control.
Results
There were three patient characteristics identified as having a significant influence on gly-
caemic control: HbA1c measurement at the beginning of the observation period (Odds
Ratio (OR) = 0.30 per 1% HbA1c increase, 95% confidence interval (CI) = 0.20–0.41); Age
(OR = 0.88 per year increase, 95% CI = 0.80–0.94), and fractional disease duration (disease
duration/age, OR = 0.80 per 0.10 increase, 95% CI = 0.66–0.93) were collectively identified
as factors contributing significantly to lower the probability of satisfactory glycaemic control.
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Conclusions
The study outcomes may prove useful for identifying paediatric patients at risk of having
unsatisfactory glycaemic control, and who could require more extensive monitoring, sup-
port, or targeted interventions.
Introduction
Appropriate glycaemic control in children and adolescents with type 1 diabetes mellitus
(T1DM) is crucial for reducing potentially serious adverse effects such as ketoacidosis,
nephropathy, microangiopathy, neuropathy and diabetic retinopathy in later stages of the dis-
ease [1]. Targeted glycaemic control to lower blood glucose levels has been shown to reduce
the risk of developing multiple complications [2,3]. Therefore, the identification of patients at
risk of poor glycaemic control before the onset of these complications is important. The man-
agement of T1DM can involve complex interactions between diet, lifestyle, medication com-
pliance, management of comorbidities, and the input of carers (e.g. parent, guardian) and
healthcare professionals (e.g. diabetes educator, dietitian, psychologist) in attempting to reduce
high blood glucose concentrations towards ‘normal’ values [4,5]. The most common means of
monitoring glycaemic control involves glycosylated haemoglobin A1c (HbA1c) measurements,
which provides a retrospective ‘longitudinal’ profile of glycaemic control over the past 2 to 3
months [6]. In assessing if a patient has appropriate glycaemic control, a simple and conve-
nient expedient involves categorisation of HbA1c measurements as ‘satisfactory’ or ‘unsatisfac-
tory’ according to a predetermined cut-off value [7]. Our endocrine paediatricians currently
use an a priori cut-off HbA1c level of9% (75 mmol/mol) as an indicator of satisfactory
glycaemic control, although trends in the HbA1c data are also considered along with an indi-
vidual’s clinical circumstances. Due to the complex nature of the endocrine system and its
pathology, and the sources of variability that influence glucose control we hypothesized that
multivariate mixed-effects, logistic regression modelling of routinely recorded clinical data
would provide a potentially useful means of identifying patient characteristics which influence
glycaemic control. Logistic regression modelling is a commonly used method of analysis for
estimating the probability (specifically via the Odds Ratio [OR]), of a variable on categorical
response data [8]. Such categorical data are frequently ‘information poor’ such that in the pres-
ent study the recorded response (dependent variable) can be 1 of only 2 possibilities (‘satisfac-
tory’ or ‘unsatisfactory’ glycaemic control). The specific aim of this study was to apply such an
approach to screen and quantify characteristics recorded routinely in the paediatric endocrine
clinic in order to develop a predictive population model which could be applied to improve
glycaemic control in young children and adolescents with T1DM.
Methods
Patients and data handling
Data were extracted from a computerised database held by the Queensland Diabetes Centre,
Mater Health Services, Brisbane, Queensland, Australia. Data from paediatric and adolescent
patients between 1 and 19 years of age who visited the Queensland Diabetes Centre between
January 1st 1998 and January 1st 2001 were included in the analysis. Prior written approval to
access the database was obtained from the ethics committees of Mater Health Services, and
The University of Queensland. The data were anonymized upon retrieval from the database.
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All data underlying this research has been included as supplementary material (S1–S3 Tables).
The dataset was stratified into a training (70%) and validation (30%) dataset. The training
dataset was used for the model development.
Information was obtained on the following patient characteristics: age, disease duration,
fractional disease duration (disease duration/age), age at diagnosis of T1DM, baseline HbA1c,
height, weight, body mass index (BMI), insulin dose per injection, total daily insulin dose, visit
interval to the hospital. Categorical variables were sex, and consultation(s) with a diabetes edu-
cator, dietitian, or psychologist over the previous 3 months. Each visit was stratified with
respect to unsatisfactory/satisfactory glycaemic control, and differences at the start of the
observation period between the two groups were tested using an independent two-sample t-
test for the continuous variables [9]. The baseline HbA1c level was the measurement obtained
at the first visit after 1st January 1998 for an individual patient. Patients who moved to Brisbane
at a later stage or changed hospitals during the observation period had fewer observations over
the study period. For modelling purposes, and for easier interpretation of the OR estimates,
the fractional disease duration variable was coded as ‘disease duration/age10’, so that an
increase of 1 is equivalent to an increase of 0.10 in fractional disease duration. Recent changes
in the guidelines for reporting HbA1c measurements are being implemented in Australia, in
order to standardize the reporting of HbA1c concentration in SI units (mmol/mol) which are
now used worldwide [10]. However, no conversion was made from the original collected data,
therefore all HbA1c concentrations are reported here as percentages, but this scaling does not
affect the subsequent analysis in any way. The cut-off HbA1c value of 9% used here is equiva-
lent to an HbA1c concentration of 75 mmol/mol [11].
Missing data
Missing values for height and weight not recorded during a consultation were replaced with
the observation at a previous or a future recorded visit of the same patient, with the timely clos-
est value chosen to replace the missing value. The corresponding BMI values of those observa-
tions were calculated with the new weight and/or height values. If multiple consecutive height
or weight observations were missing they were replaced by median height values obtained
from the World Health Organization Child Growth Standards corresponding with a patient’s
age [12], or by median weight values reported by the Centers for Disease Control and Preven-
tion for children older than 12 years [13]. Observations were not included in the analysis when
an observation of a different variable was lacking. The visit interval between a previous visit
and the first visit of the observation period was unknown, therefore this was changed to the
mean visit interval of 3.5 months.
HbA1c analysis
HbA1c levels were measured using a latex immunoagglutination inhibition assay on a DCA
2000 analyser (Bayer Diagnostics, Sydney, NSW, Australia). The validated working range for
this method ranged from 2.5% to 14.0% for HbA1c. The coefficient of variation was 2.0%–
3.4%.
Logistic regression model building
Logistic regression is commonly used to estimate the probability and the OR of a stimulus or
condition on a dichotomous response. The resulting probability estimated by the model is the
probability of the outcome being equal to 1, which in the present study represented ‘satisfactory’
glycaemic control. The stimulus represents a patient characteristic that could potentially influ-
ence the dependent variable, which presently was the achievement of satisfactory glycaemic
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control (HbA1c <9%). A mixed-effects population modelling approach using a random effects
model with variability on the intercept term was used to identify the ‘typical’ population
response, but which also preserves to an extent the ‘individuality’ of a patient’s response [14]. A
random-effects model was chosen for data analysis to increase the understanding of the under-
lying mechanism of individual risk factor on HbA1c [15]. The multivariable logistic regression
modelling strategy presently used is described more fully elsewhere [16]. Several assumptions
were tested to ensure that model outcomes were reliable. Multicollinearity was tested using a
variance inflation factor (VIF) metric to ensure that two or more explanatory variables included
in a multiple logistic regression model were not highly correlated; otherwise this could result in
a change of the regression coefficients of all affected variables, and correct interpretation of the
OR would be impossible as the outcome would not be solely influenced by a single variable. If
two patient characteristics showed high correlation (VIF>3), the least significant variable was
excluded from the model. The model was developed using a stepwise logistic regression
approach involving forward inclusion and backward elimination [16]. Inclusion of a variable
was deemed to be statistically significant at p<0.05. At each step, variables were included for
testing if deemed to be clinically or biologically plausible. The OR was calculated by taking the
natural exponent of the regression coefficients (β) estimated by the model. Model building was
continued until the addition of a new variable did not result in further statistically significant
improvement of the model. The significant improvement of the model was judged by the objec-
tive function value (OFV) which is a goodness-of-fit metric generated internally during fitting
of a model to the data, and is equal to -2  log likelihood value, which approximates a X2 distri-
bution [17]. The addition of a variable was considered to have made a significant improvement
to the fit of the model when the OFV decreased by at least 3.84 with 1 additional degree of free-
dom [9].
Model evaluation and validation
The sensitivity and the specificity of the developed model were determined using a receiver
operating characteristic (ROC) curve [18]. The ROC curve gives an insight into the predictive
value of the model in terms of its ability to correctly describe patients having/not having satis-
factory glycaemic control. The balance between high sensitivity and high specificity depends
on the goal of the study; presently we aimed to predict those patients having satisfactory con-
trol while minimizing misspecifications of the model. Consequently, the predictive ability of
the model was chosen at the middle of the arch of the ROC curve. The 95% confidence interval
on the ROC curve was generated using a 20,000 sample bootstrap. Internal validation was per-
formed using a nonparametric bootstrap analysis (with replacement) to assess the robustness
and stability of a candidate model, in which the model was fitted to 1000 randomly selected
subsets of the main data set [19]. When the 95% (2.5th– 97.5th) percentile confidence interval
(CI) of the OR included unity (i.e. no difference in OR with an increase of 1 unit), the variable
was discarded since its effect on the outcome would not be significant after bootstrap analysis.
The predictive abilities of the model were checked by estimating the probabilities of satisfac-
tory control on the validation dataset, while incorporating only the fixed effects of the final
model.
Software
Modelling was performed using NONMEM version 7.3 [17] in conjunction with Perl-speaks-
NONMEM (PsN) version 4.4.8 [20]. Data assembly and plots were generated using R version
3.3.2 in combination with RStudio version 0.99.887 [21–23]. ROC curves were created using
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the pROC package in R [24]. Multicollinearity between patient characteristics was examined
using the IBM SPSS Statistics 23 package [25].
Results
Patients and data
The data comprised 1852 HbA1c measurements in 288 patients (153 female, 135 male) with
T1DM, aged 1.2 to 19.8 years old at the start of the observation period. Fig 1A and 1B show
individual HbA1c measurements versus age, and fractional disease duration during the study
period, respectively; observations for each patient were connected to illustrate a progression
trend. The dashed lines indicate the cut-off value for HbA1c (9%) that was used for categorisa-
tion. There were a total of 897 ‘satisfactory’, and 955 ‘unsatisfactory’ HbA1c observations dur-
ing the study period. The characteristics of the patients at the beginning of the observation
period are presented in Table 1, in which the mean baseline HbA1c (HbA1c level (%) at the
beginning of the observation period) was 7.8% for patients having satisfactory glycaemic con-
trol, and 10.3% for patients having unsatisfactory control. The first clinic visit during the
observation period was on average 3.4 years after T1DM diagnosis. In both groups, patients
visited a healthcare professional in addition to an endocrinologist in 2 out of 3 hospital visits.
All patients were receiving a conventional dosage regimen of 1 to 4 subcutaneous insulin injec-
tions per day. A self-titrated combination of short- and intermediate-acting insulin was the
most common type of treatment for 259 patients (89.9%), while 11 patients (3.8%) had pre-
mixed insulin, 8 patients (2.8%) had a combination of short-acting and long-acting insulins,
Fig 1. A: HbA1c measurements (%) versus age (years). B: HbA1c measurements (%) versus fractional disease duration. Individual
lines connect all observations for a patient. Dashed lines show the HbA1c cut-off value (9%) for satisfactory glycaemic control.
https://doi.org/10.1371/journal.pone.0182181.g001
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7 patients (2.4%) had intermediate-acting insulin, 2 patients (0.7%) had a combination of
short-acting, intermediate-acting and long-acting insulin, and 1 patient (0.35%) was receiving
both short-acting and premixed insulin. The training and validation dataset had similar
patient characteristics, and summary statistics have been included as supplementary material
(S4 Table).
Model building
An overall probability of 51% of achieving satisfactory glycaemic control was estimated using a
logistic model including only the intercept term, prior to the inclusion of candidate patient
characteristics. The estimated variance (ω2) on the intercept term was estimated as 4.39. The
results of the stepwise model building are shown in Table 2. A total of 3 forward selection steps
were required to develop the final model. Inclusion of baseline HbA1c resulted in a decrease of
124 in the OFV, and this variable was retained in the model at the first step as the most signifi-
cant patient characteristic for glycaemic control. The inclusion of age also produced a signifi-
cant decrease in the OFV (-19.39). Fractional disease duration (representing the proportion of
life with diagnosed T1DM) was added as the final significant characteristic producing a signifi-
cant decrease of -11.78 in the OFV. Age at which T1DM was diagnosed and disease duration
also were significant, but both factors showed marked multicollinearity with fractional disease
duration, therefore they were subsequently excluded from the model building. No interaction
terms were retained in the final model. Backward elimination did not necessitate the removal
of any variable from the model. The ω2 on the intercept term was reduced from 4.39 to 2.93
Table 1. Patient characteristics at the start of the observation period.
Patient characteristics Satisfactory glycaemic control (HbA1c < 9%) Unsatisfactory glycaemic control (HbA1c 9%) Overall range
Total number of patients 288 -
Number of patients 169 119
Total number of observations a 897 955 -
Sex—Female 85 68 -
Sex—Male 84 51
Age (years)* 10.9 (4.39) 11.9 (4.13) 1.2–19.8
Age at diagnosis (years) 8.1 (3.95) 7.5 (4.03) 0.7–16.5
Disease duration (years)** 2.8 (3.17) 4.4 (3.80) 0.08–16.2
Fractional disease duration ** 0.24 (0.23) 0.36 (0.26) 0.01–0.93
Weight (kg)* 42.7 (18.53) 47.8 (19.65) 8.2–98.5
Height (cm) 143.6 (23.94) 148.2 (23.61) 72.5–192.6
BMI (kg/m2)* 19.5 (3.52) 20.6 (4.03) 11.7–35.7
HbA1c (%)** 7.8 (0.90) 10.3 (1.30) 5.0–14.0
Insulin dose per injection (U)** 15.9 (10.66) 20.8 (13.26) 1.5–68.5
Daily insulin dose (U)** 35.8 (25.35) 50.2 (30.85) 2.0–137
Visit Interval (months) a 3.5 (2.33) 0.12–27.8
Diabetes educatorb 98 71 -
Dietitianb 68 40
Psychologistb 54 32
Mean (sd). Fractional disease duration = disease duration/age, visit interval = time interval between two visits,
a
= during full observation period,
b
= number of patients that had a visit to a healthcare professional within the last 3 months before start of observation period,
* = p-value < 0.05,
** = p-value <0.001
https://doi.org/10.1371/journal.pone.0182181.t001
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after inclusion of all significant variables. Corresponding OR and 95%-CI estimates for the
final model after bootstrap analysis are shown in Table 3. The baseline HbA1c gave an OR of
0.30 for every 1% increase of the HbA1c measurement at the beginning of the observation
period. Age of the patient at the time of HbA1c measurement resulted in an OR of 0.88 for
every 1 year increase in age, while fractional disease duration had an OR of 0.80 per 0.10
increase in fractional disease duration.
Model evaluation and validation
The parameters included in the final model were tested for multicollinearity. VIFs were all less
than 3 indicating that there was low collinearity between variables. The ROC curves of both
the training and validation datasets (Fig 2) showed that this model was able to describe the
data in both datasets. The area-under-the-curve (AUC) of the training dataset was 91.5%
whereas the validation dataset had an AUC of 71%. The lower AUC is the result of the simu-
lated probabilities for satisfactory glycaemic control while only including the fixed effects. The
results of the bootstrap (Table 3) showed that the median values of the parameter estimates
agreed closely with the corresponding values of the final model. None of the 95% CIs for an
OR estimated in the final model included 1, indicating that all included variables provided a
significant improvement in the fit of the model to the data.
Discussion
The outcome of the mixed-effects logistic regression modelling clearly showed that glycaemic
control in the early stages of disease was the best explanatory variable of subsequent control in
young children and adolescents with T1DM; unsatisfactory control predicted poor future con-
trol. Furthermore, age and fractional disease duration also were significant predictors of
Table 2. Stepwise model building results.
Step Patient characteristic OFV ΔOFV Δdf
0 Intercept 1424.52 NA NA
1 Baseline HbA1c 1300.47 -124.05** 1
2 Age 1281.08 -19.39** 1
3 Fractional disease duration 1269.30 -11.78** 1
OFV = Objective Function Value, ΔOFV = Difference in OFV between two competing models, Δdf = degrees of freedom between two competing models,
NA = Not applicable,
** = p-value < 0.001.
https://doi.org/10.1371/journal.pone.0182181.t002
Table 3. Parameter estimates, regression coefficients and odds ratios with the 95% CI of the final multivariable logistic regression model and
bootstrap results (n = 1000).
Model estimates Bootstrap results
Patient characteristic β (RSE%) OR Median β (RSE%) Median OR OR 95% CI
Intercept 12.7 (12.9%) - 12.72 (12.98%) - -
Baseline HbA1c (%) - 1.2 (13.7%) 0.30 -1.19 (13.75%) 0.30 0.20–0.41
Age (years) - 0.13 (31%) 0.88 -0.13 (31.2%) 0.88 0.80–0.94
Fractional disease duration - 0.22 (36.2%) 0.80a -0.22 (36.13%) 0.80a 0.66–0.93
β = regression coefficient, RSE% = relative standard error in %, OR = Odds Ratio, OR 95% CI = 95% confidence interval of the odds ratio,
a
= for every 0.10 increase in fractional disease duration
https://doi.org/10.1371/journal.pone.0182181.t003
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glycaemic control. The final model predicted that patients having elevated HbA1c levels had a
higher probability of future unsatisfactory HbA1c levels. In support, previous research showed
that HbA1c at the commencement of a study period was a predictor of future glycaemic con-
trol, and that those patients with unsatisfactory glycaemic control had higher intra-individual
Fig 2. Receiver operating characteristic curves of the training (AUC = 91.5%) and validation
(AUC = 71%) models. The curved black line shows the sensitivity versus specificity of the multivariable
logistic regression models. The diagonal lines describe the random line for a model with no predictive abilities.
The blue shaded area represents the 95% confidence interval.
https://doi.org/10.1371/journal.pone.0182181.g002
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variability between HbA1c monitoring events [26]. Others reported that poor metabolic con-
trol in the second year after diagnosis was the best predictor for the HbA1c between 3 and 6
years after diagnosis. [27]. The results of other studies supported our findings in that HbA1c
levels as well as age are significant predictors of future glycaemic control [28,29].
The present study showed that a decrease in satisfactory glycaemic control and increased
variability in control in older children may partly be due to factors associated with the onset of
puberty. Fig 1A showed a large increase in variability of HbA1c levels at about 13 years of age.
Indeed, it was previously reported that decreased glycaemic control often occurs at the onset
of puberty [30,31], which may be the result of complex changes in physiology, and the influ-
ence of psychosocial factors at this age. Besides dietary changes during puberty there are surges
in human growth hormone [32], which is an insulin antagonist [33]. Decreased compliance
and frequency of blood glucose monitoring (perhaps as a reaction to perceived peer pressure),
and increased levels of stress also may affect glycaemic control in adolescents [4,34].
Two significant variables for glycaemic control were closely related; fractional disease dura-
tion and disease duration, with fractional disease duration being identified as the stronger pre-
dictor for glycaemic control. Fractional disease duration incorporates aspects of disease
duration and age of diagnosis in a single variable which is an advantage compared to imple-
menting the variables on their own. As an example, a 15-year-old patient with a disease dura-
tion of 5 years would have a fractional disease duration of 0.33, compared to a 6-year-old
patient who has been living with diabetes for 5 years where the fractional disease duration is
0.83; those living with diabetes for a longer proportion of their life are at higher risk of having
unsatisfactory HbA1c levels. Although some studies found that age at T1DM diagnosis was a
positive predictor for unsatisfactory glycaemic control [35,36], this could not be included in
the final model due to the multicollinearity issues as described above.
The mean HbA1c value of 9.16% in our patients was slightly higher than recorded for some
other studies in type 1 diabetic children [37–39], which could simply be a reflection of the fact
that many of our patients had been referred to the clinic because of significant difficulties with
their management elsewhere such as in regional areas. Consultations with healthcare profes-
sionals other than an endocrinologist did not predict a significant improvement in glycaemic
control. The fact that many patients had regular appointments with at least one healthcare pro-
fessional regardless of their current HbA1c status may partly explain why this variable did not
achieve the level of significance necessary for inclusion in the final model. Nonetheless, there
is a consensus that regular consultations with healthcare professionals to continuously educate
patients about the dosing and administration of insulin, the monitoring of blood sugar levels,
and counselling on aspects of lifestyle changes remain important for achieving satisfactory gly-
caemic control [40,41]. However, the overall effect of diabetes education for children and their
families remains equivocal [42,43], and further research on methods of education and support
in this population is required to improve the chances of better glycaemic control.
The final model resulted in an AUC of 91.5% under the ROC curve of the training dataset
and an AUC of 71% for the validation dataset, suggesting that there are other unidentified
factors which also are predictors for glycaemic control in these children. This also may be a
consequence of the amount of data available in the present study, especially since binary cate-
gorical data is relatively ‘information-poor’, compared to continuous data. Thus, the discrimi-
natory power of such an analysis could be augmented with increased amounts of data.
Therefore, data collection needs to be extended to other centers both in Australia and else-
where. The data used in the present modelling have been provided which may facilitate an
external validation of the identified predictive patient characteristics in the study. The final
model was able to identify patients with satisfactory/unsatisfactory control in approximately
85% of cases using the 3 most significant factors which are routinely documented in T1DM.
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There are multiple hazards and pitfalls associated with multivariable logistic regression
modelling, and while this approach is often used in biomedical research many published stud-
ies have not embraced the rigor needed to correctly asses the value, stability, or significance of
the reported models [44,45]. Presently, our paediatric patients with T1DM are a ‘difficult’
cohort of patients in which there is considerable variability, together with the risk of confound-
ing variables and multicollinearity. In view of the rapid increase in the prevalence of diabetes
in children and adults [46], this study is timely and relevant and illustrates how a multivariable
logistic regression modelling approach has much potential for application in the therapeutics
and epidemiology of type 1 diabetes. It was recognised from the outset that the format of the
data had to be categorical in nature, because the outcome of direct interest to our endocrinolo-
gists was whether a given patient’s glycaemic control fell above or below an a priori HbA1c
threshold. In future studies it may be of interest to also model more information-rich data
using the actual HbA1c level as a continuous dependent variable.
In conclusion, the present study identified and quantified the influence of several factors in
a mixed-effects (population) logistic regression model that has the potential to assist clinicians
to identify paediatric patients who are at increased risk of having unsatisfactory glycaemic con-
trol, and who would require more extensive monitoring, support, or targeted interventions.
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